Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Recs

1
Player Avatar xserver (98.58) Submitted: 11/27/2011 5:28:58 PM : Outperform Start Price: $10.66 DNDN Score: -70.63

Admittedly ignorant about biotechs. So, that is why it is here and not in my real portfolio.

Featured Broker Partners


Advertisement